Kevin Peters

Kevin Peters

Company: Aerpio Pharmaceuticals

Job title: Chief Scientific & Medical Officer & Senior Vice President


Dr. Peters guided the early preclinical and clinical development of Aerpio’s VE-PTP targeted Tie2 activators, and currently leads scientific discovery and translational development for Aerpio. He was formerly the Group Medical Director, CV and Metabolic Disease in Global and Discovery Medicine at Bristol Myers Squibb and head of Therapeutic Angiogenesis research at Proctor & Gamble Pharmaceuticals. Prior to that, Dr. Peters was an Associate Professor of Medicine and Pharmacology in the Division of Cardiology at Duke University Medical Center. Dr. Peters received his M.D. from the University of Iowa and was a Research Fellow and Adjunct Professor at the University of California, San Francisco. Dr. Peters has published broadly in the areas of growth factor receptor signaling and vascular biology and has led several preclinical programs to clinical proof of concept in vascular and metabolic diseases.


Chair-Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF 4:30 pm

Read more

day: Day One

Targeting the Tie2 Pathway for Vision Threatening Retinopathy 4:05 pm

VE-PTP inhibition is an effective pharmacologic approach to activate Tie2 Combining Tie2 activation via VE-PTP inhibition with anti-VEGF agents improves outcomes Aerpio’s novel bispecific biologic simultaneously activates Tie2 and inhibits VEGFR2 activationRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.